Analysts think AURA stock price could increase by 162%
Nov 23, 2024, 12:26 PM
-8.38%
What does AURA do
Aura Biosciences, a clinical-stage oncology company based in Boston, develops virus-like drug conjugates (VDCs) to selectively target cancer cells and activate immune responses. Its lead candidate, bel-sar, is in late-stage clinical development for choroidal melanoma and bladder cancer.
9 analysts think AURA stock price will increase by 162.12%. The current median analyst target is $23.46 compared to a current stock price of $8.95. The lowest analysts target is $20.20 and the highest analyst target is $25.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.